Obsessive-Compulsive Disorder
Conditions
Keywords
OCD, Microbiome, FMT, Gut bacteria
Brief summary
Obsessive-compulsive disorder (OCD) is a psychiatric condition marked by recurrent intrusive thoughts (obsessions) and ritualistic behaviors aimed at reducing distress (compulsions). While there exist a number of medications to treat this illness, half of those who need them either do not respond or can not tolerate current medications because of side effects. Therefore, there is an urgent need to develop new ways to treat this illness. One of the areas being explored as a potential option is based on what is now known as a strong link between the bacteria that live in our gut and the brain. Research has shown that a fecal transplant of the gut bacteria from healthy donors is able to improve health outcomes for people with depression and the investigators now want to expand this into OCD, given a known link between this condition and bacterial infection. To do this the investigators will use both the standard methods of bacterial identification via stool analysis, which looks at large bowel changes, and compare it to the Small Intestine Microbiome Aspiration (SIMBA) system, a small capsule that when swallowed allows a fluid sample to be collected from the participants' small intestine. This work will help the investigators assess the benefits of fecal transplant in OCD, and more importantly, identify how transplant changes the system, utilizing a novel technology to move the field forward.
Interventions
COMBINATION_PRODUCTFMT Capsule + SIMBA Capsule
Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
Sponsors
Nimble Science Ltd.
University of Calgary
Valerie Taylor
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adults who have a primary diagnosis of OCD * on a stable appropriate dose of (SSRI) treatment for at least 12 weeks prior to Baseline * insufficient response to current SSRI treatment indicated by persistence of symptoms.
Exclusion criteria
* Participant meets Diagnostic criteria for substance use, eating disorder, schizophrenia, or schizoaffective disorder * Suicidality * regular intake of antibiotics, prebiotics, or probiotics * Clinically diagnosed with IBD, Crohn's disease, Ulcerative colitis, or Celiac disease * Immune suppression * intestinal obstruction * Oropharyngeal dysphagia or other swallowing disorder * \< 2 bowel movements per week * Breastfeeding, pregnant or seeking to get pregnant during the course of this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 0-13 weeks | Reported Adverse events |
| Toronto Side Effects Scale (TSES) | 0-13 weeks | Changes in the Toronto Side Effects Scale (TSES). TSES a 32-item instrument used to evaluate the incidence, frequency, and severity of the central nervous system (CNS), gastrointestinal (GI), and sexual side effects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global function/overall improvement (Positive and Negative Affect Schedule (PANAS)) | 0-13 weeks | Positive and Negative Affect Schedule (PANAS). The PANAS is a self-report questionnaire that consists of two 10-item scales and measures both positive and negative emotions for participants. The total score is calculated by finding the sum of the 10 positive items, and then the 10 negative items. Scores range from 10 - 50 for both sets of items. higher score indicates more positive or negative affect respectively. |
| Global function/overall improvement (Patient Health Questionnaire-9(PHQ9)) | 0-13 weeks | Patient Health Questionnaire-9(PHQ9). The PHQ9 is used for screening and measuring the severity of depressive symptoms. The total score is the sum the numbers of all the checked responses under each heading. Cut off scores are: 0 - 4 None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe and 20 - 27 Severe. |
| Global function/overall improvement (Quick Inventory of Depressive Symptomatology-Self-Report (QIDS)) | 0-13 weeks | Quick Inventory of Depressive Symptomatology-Self-Report (QIDS). is a 16-item questionnaire that rates depression symptoms via self-assessment. Toral score is calculated but summing the scores of each of the 16 different questions. 0-5 Normal, 6-10 mild depression, 11-15 Moderate depression, 16-20 Severe depression and \>21 is considered very severe depression. |
| OCD symptoms (TOCS) | 0-13 weeks | Toronto Obsessive-Compulsive Scale (TOCS). TOCS is a 21 item self-reported questionnaire that assesses several major symptom dimensions in OCD. A total score is calculated by adding each score of the 21 items, and dimension scores are calculated by averaging the sum of item scores within each dimension. |
| Next generation fecal, Urine, Blood and saliva sequencing | 0-13 weeks | analysis of Fecal, urine, blood and saliva samples |
| OCD symptoms (Y-BOCS) | 0-13 weeks | Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Total scores range from 0 to 40. 0-7 indicates subclinical symptoms, 8-15 mild symptoms, 16-23 moderate symptoms, 24-31 severe symptoms and 32-40 extreme symptoms |
| Global function/overall improvement (The General Anxiety Disorder-7 scale (GAD-7)) | 0-13 weeks | The General Anxiety Disorder-7 scale (GAD-7). The 7-item tool is used to screen and assess for generalized anxiety. Score 0-4: Minimal Anxiety, Score 5-9: Mild Anxiety, Score 10-14: Moderate Anxiety and Score greater than 15: Severe Anxiety |
Countries
Canada
Contacts
Primary ContactAsem Bala, Msc, CCRP
Backup ContactVivek Kumar, MD
Outcome results
None listed